AMP-DNM

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: AMP-DNM
• 英文别名: N-[5-(adamantan-1-yl-methoxy)-pentyl]-1-deoxynojirimycin；N-(adamantanemethyloxypentyl)deoxynojirimycin；(2R,3R,4R,5S)-1-(5-(((3R,5R,7R)-adamantan-1-yl)methoxy)pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol；N-adamantanemethyloxypentyl-1-deoxynojirimycin；(2R,3R,4R,5S)-1–(5-(adamantan-1-ylmethoxy)pentyl)-2-(hydroxymethyl)piperidine-3,4,5-triol；AMP-Deoxynojirimycin；(2R,3R,4R,5S)-1-[5-(1-adamantylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
• 化学式: C₂₂H₃₉NO₅
• 分子量: 397.555
• InChiKey: XVYLNHVEAOOEGI-FAIWKWDXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  93.4
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  AMP-DNM 、 甲烷磺酸 以 异丙醇 为溶剂， 以65%的产率得到N-[5-(adamantan-1-yl-methoxy)pentyl]-1-deoxynojirimycin methanesulfonic acid salt
  参考文献：
  名称：

  葡萄糖基神经酰胺合酶抑制剂N- [5-（5-金刚烷-1-基-甲氧基）-戊基] -1-脱氧野oji霉素的大规模合成

  摘要：

  已开发出制备葡萄糖基神经酰胺合酶抑制剂N- [5-（金刚烷-1-基-甲氧基）-戊基] -1-脱氧野oji霉素甲磺酸盐（AMP-DNM）的合成途径。本文中，我们报告了这种合成路线的开发和优化过程，从最初的毫克级学术研究实验室版本发展到最终的最佳路线，该路线已在cGMP微型工厂中以千克规模实施。明确的路线始于对结构2,3,4,6-tetra- O的单独合成-苄基-1-脱氧野oji霉素和5-（金刚烷-1-基甲氧基）-戊醛。该醛是由1，5-戊二醇分五个步骤合成的，总产率为45％。通过连续的2,3,4,5-四-O-苄基-d半缩醛还原/ Swern氧化/双重还原胺化序列制备受保护的1-脱氧野oji霉素-吡喃葡萄糖的总产率为52％。两个构件的还原胺化产生了苄基保护的倒数第二个化合物，其结晶（+）DTTA盐被分离出来，产率为68％。倒数第二位的氢解和最终产物的甲磺酸盐结晶产生AMP-DNM，收率76％，纯度>

  DOI：

  10.1021/op700295x
• 作为产物：
  描述：

  5-hydroxypentyl p-toluenesulfonate 在 盐酸 、 sodium hypochlorite 、 2,2,6,6-四甲基哌啶氧化物 、 palladium on activated charcoal 、 氢气 、 sodium hydride 、 碳酸氢钠 、 对甲苯磺酸 、 溶剂黄146 、 sodium chloride 、 potassium bromide 、 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 、 甲基叔丁基醚 、 水 、 N,N-二甲基甲酰胺 、 丙酮 、 mineral oil 为溶剂， 反应 53.92h， 生成 AMP-DNM
  参考文献：
  名称：

  葡萄糖基神经酰胺合酶抑制剂N- [5-（5-金刚烷-1-基-甲氧基）-戊基] -1-脱氧野oji霉素的大规模合成

  摘要：

  已开发出制备葡萄糖基神经酰胺合酶抑制剂N- [5-（金刚烷-1-基-甲氧基）-戊基] -1-脱氧野oji霉素甲磺酸盐（AMP-DNM）的合成途径。本文中，我们报告了这种合成路线的开发和优化过程，从最初的毫克级学术研究实验室版本发展到最终的最佳路线，该路线已在cGMP微型工厂中以千克规模实施。明确的路线始于对结构2,3,4,6-tetra- O的单独合成-苄基-1-脱氧野oji霉素和5-（金刚烷-1-基甲氧基）-戊醛。该醛是由1，5-戊二醇分五个步骤合成的，总产率为45％。通过连续的2,3,4,5-四-O-苄基-d半缩醛还原/ Swern氧化/双重还原胺化序列制备受保护的1-脱氧野oji霉素-吡喃葡萄糖的总产率为52％。两个构件的还原胺化产生了苄基保护的倒数第二个化合物，其结晶（+）DTTA盐被分离出来，产率为68％。倒数第二位的氢解和最终产物的甲磺酸盐结晶产生AMP-DNM，收率76％，纯度>

  DOI：

  10.1021/op700295x

文献信息

• A Fluorescence Polarization Activity-Based Protein Profiling Assay in the Discovery of Potent, Selective Inhibitors for Human Nonlysosomal Glucosylceramidase
  作者：Daniël Lahav、Bing Liu、Richard J. B. H. N. van den Berg、Adrianus M. C. H. van den Nieuwendijk、Tom Wennekes、Amar T. Ghisaidoobe、Imogen Breen、Maria J. Ferraz、Chi-Lin Kuo、Liang Wu、Paul P. Geurink、Huib Ovaa、Gijsbert A. van der Marel、Mario van der Stelt、Rolf G. Boot、Gideon J. Davies、Johannes M. F. G. Aerts、Herman S. Overkleeft

  DOI：10.1021/jacs.7b07352

  日期：2017.10.11

  assessed on GBA2 selectivity offset against the other glucosylceramide metabolizing enzymes, glucosylceramide synthase (GCS), lysosomal glucosylceramidase (GBA), and the cytosolic retaining β-glucosidase, GBA3. Our work, yielding potent and selective GBA2 inhibitors, also provides a roadmap for the development of high-throughput assays for identifying retaining glycosidase inhibitors by FluoPol-ABPP

  人非溶酶体葡萄糖基神经酰胺酶（GBA2）是控制糖脂水平的几种酶之一，其活性与几种人类疾病状态相关。迫切需要设计或发现选择性的GBA2抑制剂作为化学工具和潜在的治疗剂。在这里，我们描述了基于荧光偏振活性的蛋白质谱分析（FluoPol-ABPP）测定法的发展，该测定法可从350多种亚氨基糖文库中快速鉴定GBA2抑制剂。基于FluoPol-ABPP筛选的线索生成聚焦库，并针对与其他葡糖神经酰胺代谢酶，葡糖神经酰胺合酶（GCS），溶酶体葡糖神经酰胺酶（GBA）和胞质保留β-葡糖苷酶GBA3的GBA2选择性偏移进行评估。我们的工作产生了有效的和选择性的GBA2抑制剂，
• Development of Adamantan-1-yl-methoxy-Functionalized 1-Deoxynojirimycin Derivatives as Selective Inhibitors of Glucosylceramide Metabolism in Man
  作者：Tom Wennekes、Richard J. B. H. N. van den Berg、Wilma Donker、Gijsbert A. van der Marel、Anneke Strijland、Johannes M. F. G. Aerts、Herman S. Overkleeft

  DOI：10.1021/jo061280p

  日期：2007.2.1

  In this article, we present a straightforward synthesis of adamantan-1-yl-methoxy-functionalized 1-deoxynojirimycin derivatives. The used synthetic routes are flexible and can be used to create a wide variety of lipophilic mono- and difunctionalized 1-deoxynojirimycin derivatives. The compounds reported here are lipophilic iminosugar based on lead compound 4, a potent inhibitor of the three enzymes

  在本文中，我们介绍了金刚烷-1-基-甲氧基官能化的1-deoxynojirimycin衍生物的直接合成。所使用的合成路线是灵活的，并且可以用于产生多种亲脂性的单和双官能化的1-脱氧野oji霉素衍生物。此处报道的化合物是基于铅化合物4的亲脂性亚氨基糖，这是一种与糖鞘脂性葡萄糖基神经酰胺代谢有关的三种酶的有效抑制剂。在过去的十年中，基于氨基糖的葡糖神经酰胺合成酶抑制剂（这三种酶之一）受到了越来越多的关注，因为该酶在鞘糖脂生物合成中起着至关重要的作用。结合越来越多的病理过程与过量的鞘糖脂水平相关的事实，葡萄糖基神经酰胺合酶成为非常有吸引力的治疗和研究目标。我们在这里提出的结果证明，将亲脂部分从氮原子重新定位到1-deoxynojirimycin环系统上的其他位置不会导致更有效或更具选择性的葡糖神经酰胺合酶抑制剂。的β氮杂Ç糖苷类似物（17）保留了对葡糖神经酰胺合酶的最佳抑制效力，并且是比治疗剂N
• Identification and Development of Biphenyl Substituted Iminosugars as Improved Dual Glucosylceramide Synthase/Neutral Glucosylceramidase Inhibitors
  作者：Amar T. Ghisaidoobe、Richard J. B. H. N. van den Berg、Saleem S. Butt、Anneke Strijland、Wilma E. Donker-Koopman、Saskia Scheij、Adrianus M. C. H. van den Nieuwendijk、Gerrit-Jan Koomen、Arnold van Loevezijn、Mark Leemhuis、Tom Wennekes、Mario van der Stelt、Gijsbert A. van der Marel、Constant A. A. van Boeckel、Johannes M. F. G. Aerts、Herman S. Overkleeft

  DOI：10.1021/jm501181z

  日期：2014.11.13

  This work details the evaluation of a number of N-alkylated deoxynojirimycin derivatives on their merits as dual glucosylceramide synthase/neutral glucosylceramidase inhibitors. Building on our previous work, we synthesized a series of d-gluco and l-ido-configured iminosugars N-modified with a variety of hydrophobic functional groups. We found that iminosugars featuring N-pentyloxymethylaryl substituents are considerably more potent inhibitors of glucosylceramide synthase than their aliphatic counterparts. In a next optimization round, we explored a series of biphenyl-substituted iminosugars of both configurations (d-gluco and l-ido) with the aim to introduce structural features known to confer metabolic stability to drug-like molecules. From these series, two sets of molecules emerge as lead series for further profiling. Biphenyl-substituted l-ido-configured deoxynojirimycin derivatives are selective for glucosylceramidase and the nonlysosomal glucosylceramidase, and we consider these as leads for the treatment of neuropathological lysosomal storage disorders. Their d-gluco-counterparts are also potent inhibitors of intestinal glycosidases, and because of this characteristic, we regard these as the prime candidates for type 2 diabetes therapeutics.
• Process Development of a Potent Glucosylceramide Synthase Inhibitor
  作者：Christopher G.F. Cooper、Edward R. Lee、Richard A. Silva、André J. Bourque、Scott Clark、Sanjeev Katti、Vitaly Nivorozhkin

  DOI：10.1021/op2001222

  日期：2012.5.18

  An economic, scalable process for the production of glucosylceramide synthase (GCS) inhibitor 7 has been developed. Herein we report a three-step synthesis to aldehyde 4 with high yield and purity that employs the selective cleavage of an endocyclic C-O bond of a THP ether using borane/THF as the key step. This particular methodology has not been used previously from a development standpoint and offers an attractive way towards introducing pentanol side chains. Aldehyde 4 is then coupled with deoxynojirimycin via flow hydrogenation using an H-Cube to safely produce the free base of 7, which is isolated as an MSA salt in 50% overall yield. Herein we discuss the evolution of this process from its original form and the thermodynamics of its associated chemistry.
• TREATMENT OF CYSTIC FIBROSIS
  申请人：Aerts Johannes Maria Franciscus Gerardus

  公开号：US20090186862A1

  公开（公告）日：2009-07-23

  The present invention discloses a therapeutic target for the treatment of cystic fibrosis. It was found that inhibition of non-lysosomal glucosylceramidase (GBA2) sufficiently restores chloride current in cells from CF patients carrying the common delF508-CFTR mutation. With the catalytic centre (4) of the enzyme positioned on top of the membrane bilayer face particularly potent inhibitors are found in deoxynojirimycin derivatives having a group that is capable of inserting in the membrane bilayer.